The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1388
April 16, 2012
View Complete Issue         Table of Contents 2019 
Tafluprost (Zioptan) - A New Topical Prostaglandin for Glaucoma
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Tafluprost (Zioptan) - A New Topical Prostaglandin for Glaucoma
April 16, 2012 (Issue: 1388)
The FDA has approved tafluprost ophthalmic solution (Zioptan – Merck), a prostaglandin analog, for reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It is being marketed as the first...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Tafluprost (Zioptan) - A New Topical Prostaglandin for Glaucoma
Article code: 1388c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.